RAGE overexpression confers a metastatic phenotype to the WM115 human primary melanoma cell line

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 7, 2014, Pages 1017-1027

  Meghnani, Varsha ^a   Vetter, Stefan W ^a   Leclerc, Estelle ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Melanoma; Metastatic switch; P53 cancer; RAGE; S100B

Indexed keywords

ACTIN; ADVANCED GLYCATION END PRODUCT RECEPTOR; CYCLIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MESENCHYME; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION;

MELANOMA; METASTATIC SWITCH; P53 CANCER; RAGE; S100B;

ANTIGENS, NEOPLASM; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CYCLIN E; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM METASTASIS; NF-KAPPA B; PHENOTYPE; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897471681     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.02.013     Document Type: Article

References (93)

1. Brett J., Schmidt A.M., Yan S.D., Zou Y.S., Weidman E., Pinsky D., Nowygrod R., Neeper M., Przysiecki C., Shaw A., et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 1993, 143:1699-1712.
2. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 2000, 1498:99-111.
3. Schmidt A.M., Vianna M., Gerlach M., Brett J., Ryan J., Kao J., Esposito C., Hegarty H., Hurley W., Clauss M., et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 1992, 267:14987-14997.
4. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D., Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 1992, 267:14998-15004.
5. Huttunen H.J., Rauvala H. Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J. Intern. Med. 2004, 255:351-366.
6. Schmidt A.M., Hasu M., Popov D., Zhang J.H., Chen J., Yan S.D., Brett J., Cao R., Kuwabara K., Costache G., et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8807-8811.
7. Alexiou P., Chatzopoulou M., Pegklidou K., Demopoulos V.J. RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr. Med. Chem. 2010, 17:2232-2252.
8. Bucciarelli L.G., Ananthakrishnan R., Hwang Y.C., Kaneko M., Song F., Sell D.R., Strauch C., Monnier V.M., Yan S.F., Schmidt A.M., Ramasamy R. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 2008, 57:1941-1951.
9. Crunkhorn S. Neurodegenerative disease: taming the RAGE of Alzheimer's disease. Nat. Rev. Drug Discov. 2012, 11:351.
10. Ramasamy R., Schmidt A.M. Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure. Curr. Heart Fail. Rep. 2012, 9:107-116.
11. Chavakis T., Bierhaus A., Al-Fakhri N., Schneider D., Witte S., Linn T., Nagashima M., Morser J., Arnold B., Preissner K.T., Nawroth P.P. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 2003, 198:1507-1515.
12. Hsieh H.L., Schafer B.W., Sasaki N., Heizmann C.W. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem. Biophys. Res. Commun. 2003, 307:375-381.
13. Kuniyasu H., Chihara Y., Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int. J. Cancer 2003, 104:722-727.
14. Kuniyasu H., Oue N., Wakikawa A., Shigeishi H., Matsutani N., Kuraoka K., Ito R., Yokozaki H., Yasui W. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J. Pathol. 2002, 196:163-170.
15. Kang R., Loux T., Tang D., Schapiro N.E., Vernon P., Livesey K.M., Krasinskas A., Lotze M.T., Zeh H.J. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:7031-7036.
16. Radia A.M., Yaser A.M., Ma X., Zhang J., Yang C., Dong Q., Rong P., Ye B., Liu S., Wang W. Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines. Int. J. Mol. Sci. 2013, 14:7959-7978.
17. Yaser A.M., Huang Y., Zhou R.R., Hu G.S., Xiao M.F., Huang Z.B., Duan C.J., Tian W., Tang D.L., Fan X.G. The role of receptor for advanced glycation end products (RAGE) in the proliferation of hepatocellular carcinoma. Int. J. Mol. Sci. 2012, 13:5982-5997.
18. Bartling B., Demling N., Silber R.E., Simm A. Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products. Am. J. Respir. Cell Mol. Biol. 2006, 34:83-91.
19. Riuzzi F., Sorci G., Donato R. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am. J. Pathol. 2007, 171:947-961.
20. Logsdon C.D., Fuentes M.K., Huang E.H., Arumugam T. RAGE and RAGE ligands in cancer. Curr. Mol. Med. 2007, 7:777-789.
21. Riehl A., Nemeth J., Angel P., Hess J. The receptor RAGE: bridging inflammation and cancer. Cell Commun. Signal. 2009, 7:12.
22. Sparvero L.J., Asafu-Adjei D., Kang R., Tang D., Amin N., Im J., Rutledge R., Lin B., Amoscato A.A., Zeh H.J., Lotze M.T. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J. Transl. Med. 2009, 7:17.
23. Leclerc E., Heizmann C.W., Vetter S.W. RAGE and S100 protein transcription levels are highly variable in human melanoma tumors and cells. Gen. Physiol. Biophys. 2009, 28:F65-F75. (Spec No Focus).
24. Abe R., Shimizu T., Sugawara H., Watanabe H., Nakamura H., Choei H., Sasaki N., Yamagishi S., Takeuchi M., Shimizu H. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J. Invest. Dermatol. 2004, 122:461-467.
25. Saha A., Lee Y.C., Zhang Z.J., Chandra G., Su S.B., Mukherjee A.B. Lack of an endogenous anti-inflammatory protein in mice enhances colonization of B16F10 melanoma cells in the lungs. J. Biol. Chem. 2010, 285:10822-10831.
26. Hoek K.S., Eichhoff O.M., Schlegel N.C., Dobbeling U., Kobert N., Schaerer L., Hemmi S., Dummer R. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 2008, 68:650-656.
27. Harpio R., Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin. Biochem. 2004, 37:512-518.
28. Donato R. S100B's double life: intracellular and extracellular signal. Biochem. Biophys. Acta Mol. Cell Res. 2009, 1793:1008-1022.
29. Kruijff S., Hoekstra H.J. The current status of S-100B as a biomarker in melanoma. Eur. J. Surg. Oncol. 2012, 38:281-285.
30. Darzynkiewicz Z., Juan G., Bedner E. Determining cell cycle stages by flow cytometry. Curr. Protoc. Cell Biol. 1999, 8:1-18.
31. Smith S.P., Barber K.R., Dunn S.D., Shaw G.S. Structural influence of cation binding to recombinant human brain S100b: evidence for calcium-induced exposure of a hydrophobic surface. Biochemistry 1996, 35:8805-8814.
32. Abramoff M.D., Magalhaes P.J., Ram S.J. Image processing with ImageJ. Biophoton. Int. 2004, 11:36-42.
33. Rampersad S.N. Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors (Basel) 2012, 12:12347-12360.
34. Leclerc E., Fritz G., Weibel M., Heizmann C.W., Galichet A. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J. Biol. Chem. 2007, 282:31317-31331.
35. Sturchler E., Galichet A., Weibel M., Leclerc E., Heizmann C.W. Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J. Neurosci. 2008, 28:5149-5158.
36. Herlyn M., Thurin J., Balaban G., Bennicelli J.L., Herlyn D., Elder D.E., Bondi E., Guerry D., Nowell P., Clark W.H., et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res. 1985, 45:5670-5676.
37. Herlyn M., Balaban G., Bennicelli J., Guerry D.T., Halaban R., Herlyn D., Elder D.E., Maul G.G., Steplewski Z., Nowell P.C., et al. Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J. Natl. Cancer Inst. 1985, 74:283-289.
38. Simmons D.P., Andreola F., De Luca L.M. Human melanomas of fibroblast and epithelial morphology differ widely in their ability to synthesize retinyl esters. Carcinogenesis 2002, 23:1821-1830.
39. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009, 28:15-33.
40. Haynes J., Srivastava J., Madson N., Wittmann T., Barber D.L. Dynamic actin remodeling during epithelial-mesenchymal transition depends on increased moesin expression. Mol. Biol. Cell 2011, 22:4750-4764.
41. Mori S., Chang J.T., Andrechek E.R., Matsumura N., Baba T., Yao G., Kim J.W., Gatza M., Murphy S., Nevins J.R. Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 2009, 28:2796-2805.
42. Guadamillas M.C., Cerezo A., Del Pozo M.A. Overcoming anoikis-pathways to anchorage-independent growth in cancer. J. Cell Sci. 2011, 124:3189-3197.
43. Kim Y.N., Koo K.H., Sung J.Y., Yun U.J., Kim H. Anoikis resistance: an essential prerequisite for tumor metastasis. Int. J. Cell Biol. 2012, 2012:306879.
44. Weinberg R.A. The Biology of Cancer 2007, (New York). Garland Science (Ed.).
45. Rustandi R.R., Baldisseri D.M., Weber D.J. Structure of the negative regulatory domain of p53 bound to S100B(betabeta). Nat. Struct. Biol. 2000, 7:570-574.
46. Fernandez-Fernandez M.R., Rutherford T.J., Fersht A.R. Members of the S100 family bind p53 in two distinct ways. Protein Sci. 2008, 17:1663-1670.
47. Chaturvedi M.M., Sung B., Yadav V.R., Kannappan R., Aggarwal B.B. NF-kappaB addiction and its role in cancer: 'one size does not fit all'. Oncogene 2011, 30:1615-1630.
48. Yang J., Splittgerber R., Yull F.E., Kantrow S., Ayers G.D., Karin M., Richmond A. Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J. Clin. Invest. 2010, 120:2563-2574.
49. Ueda Y., Richmond A. NF-kappaB activation in melanoma. Pigment Cell Res. 2006, 19:112-124.
50. Zink D., Fischer A.H., Nickerson J.A. Nuclear structure in cancer cells. Nat. Rev. Cancer 2004, 4:677-687.
51. Khatau S.B., Hale C.M., Stewart-Hutchinson P.J., Patel M.S., Stewart C.L., Searson P.C., Hodzic D., Wirtz D. A perinuclear actin cap regulates nuclear shape. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19017-19022.
52. Huttunen H.J., Fages C., Kuja-Panula J., Ridley A.J., Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 2002, 62:4805-4811.
53. Hoek K., Rimm D.L., Williams K.R., Zhao H., Ariyan S., Lin A., Kluger H.M., Berger A.J., Cheng E., Trombetta E.S., Wu T., Niinobe M., Yoshikawa K., Hannigan G.E., Halaban R. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 2004, 64:5270-5282.
54. Haqq C., Nosrati M., Sudilovsky D., Crothers J., Khodabakhsh D., Pulliam B.L., Federman S., Miller J.R., Allen R.E., Singer M.I., Leong S.P., Ljung B.M., Sagebiel R.W., Kashani-Sabet M. The gene expression signatures of melanoma progression. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:6092-6097.
55. Smith A.P., Hoek K., Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol. Ther. 2005, 4:1018-1029.
56. Jaeger J., Koczan D., Thiesen H.J., Ibrahim S.M., Gross G., Spang R., Kunz M. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin. Cancer Res. 2007, 13:806-815.
57. Matsumoto Y., Maller J.L. A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry. Science 2004, 306:885-888.
58. Simmons D.P., Peach M.L., Friedman J.R., Green M.M., Nicklaus M.C., De Luca L.M. Evidence that sequence homologous region in LRAT-like proteins possesses anti-proliferative activity and DNA binding properties: translational implications and mechanism of action. Carcinogenesis 2006, 27:693-707.
59. Satyamoorthy K., Chehab N.H., Waterman M.J., Lien M.C., El-Deiry W.S., Herlyn M., Halazonetis T.D. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ. 2000, 11:467-474.
60. Lin J., Blake M., Tang C., Zimmer D., Rustandi R.R., Weber D.J., Carrier F. Inhibition of p53 transcriptional activity by the S100B calcium-binding protein. J. Biol. Chem. 2001, 276:35037-35041.
61. Lin J., Yang Q., Wilder P.T., Carrier F., Weber D.J. The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J. Biol. Chem. 2010, 285:27487-27498.
62. Lin J., Yang Q., Yan Z., Markowitz J., Wilder P.T., Carrier F., Weber D.J. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J. Biol. Chem. 2004, 279:34071-34077.
63. Gadea G., de Toledo M., Anguille C., Roux P. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J. Cell Biol. 2007, 178:23-30.
64. Ishihara K., Tsutsumi K., Kawane S., Nakajima M., Kasaoka T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett. 2003, 550:107-113.
65. Hudson B.I., Kalea A.Z., Del Mar Arriero M., Harja E., Boulanger E., D'Agati V., Schmidt A.M. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J. Biol. Chem. 2008, 283:34457-34468.
66. Sakaguchi M., Murata H., Yamamoto K., Ono T., Sakaguchi Y., Motoyama A., Hibino T., Kataoka K., Huh N.H. TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding. PLoS One 2011, 6:e23132.
67. Becker T.M., Philipsz S., Scurr L.L., Fung C., Haferkamp S., Kefford R.F., Rizos H. Oncogenic B-RAF(V600E) promotes anchorage-independent survival of human melanocytes. J. Invest. Dermatol. 2010, 130:2144-2147.
68. Klein R.M., Spofford L.S., Abel E.V., Ortiz A., Aplin A.E. B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol. Biol. Cell 2008, 19:498-508.
69. Kudo-Saito C., Shirako H., Takeuchi T., Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009, 15:195-206.
70. Shin S.I., Freedman V.H., Risser R., Pollack R. Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc. Natl. Acad. Sci. U. S. A. 1975, 72:4435-4439.
71. Wellbrock C., Rana S., Paterson H., Pickersgill H., Brummelkamp T., Marais R. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One 2008, 3:e2734.
72. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
73. Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003, 63:5198-5202.
74. Stecca B., Mas C., Clement V., Zbinden M., Correa R., Piguet V., Beermann F., Ruiz I.A.A. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5895-5900.
75. Li G., Xu J., Li Z. Receptor for advanced glycation end products inhibits proliferation in osteoblast through suppression of Wnt, PI3K and ERK signaling. Biochem. Biophys. Res. Commun. 2012, 423:684-689.
76. Palmieri G., Capone M., Ascierto M.L., Gentilcore G., Stroncek D.F., Casula M., Sini M.C., Palla M., Mozzillo N., Ascierto P.A. Main roads to melanoma. J. Transl. Med. 2009, 7:86.
77. Davies M.A. The role of the PI3K-AKT pathway in melanoma. Cancer J. 2012, 18:142-147.
78. Lopez-Bergami P., Huang C., Goydos J.S., Yip D., Bar-Eli M., Herlyn M., Smalley K.S., Mahale A., Eroshkin A., Aaronson S., Ronai Z. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 2007, 11:447-460.
79. Dattilo B.M., Fritz G., Leclerc E., Kooi C.W., Heizmann C.W., Chazin W.J. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 2007, 46:6957-6970.
80. Ostendorp T., Leclerc E., Galichet A., Koch M., Demling N., Weigle B., Heizmann C.W., Kroneck P.M., Fritz G. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J. 2007, 26:3868-3878.
81. Moroz O.V., Antson A.A., Dodson E.J., Burrell H.J., Grist S.J., Lloyd R.M., Maitland N.J., Dodson G.G., Wilson K.S., Lukanidin E., Bronstein I.B. The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr. D Biol. Crystallogr. 2002, 58:407-413.
82. Zong H., Madden A., Ward M., Mooney M.H., Elliott C.T., Stitt A.W. Homodimerisation is essential for the receptor for advanced glycation end-products (RAGE)-mediated signal transduction. J. Biol. Chem. 2010, 285:23137-23146.
83. Sitkiewicz E., Tarnowski K., Poznanski J., Kulma M., Dadlez M. Oligomerization interface of RAGE receptor revealed by MS-monitored hydrogen deuterium exchange. PLoS One 2013, 8:e76353.
84. Xu D., Young J.H., Krahn J.M., Song D., Corbett K.D., Chazin W.J., Pedersen L.C., Esko J.D. Stable RAGE-heparan sulfate complexes are essential for signal transduction. ACS Chem. Biol. 2013, 8:1611-1620.
85. Yatime L., Andersen G.R. Structural insights into the oligomerization mode of the human receptor for advanced glycation end-products. FEBS J. 2013, 280:6556-6568.
86. Wei W., Lampe L., Park S., Vangara B.S., Waldo G.S., Cabantous S., Subaran S.S., Yang D., Lakatta E.G., Lin L. Disulfide bonds within the C2 domain of RAGE play key roles in its dimerization and biogenesis. PLoS One 2012, 7:e50736.
87. Xie J., Reverdatto S., Frolov A., Hoffmann R., Burz D.S., Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J. Biol. Chem. 2008, 283:27255-27269.
88. Zong H., Madden A., Ward M., Mooney M.H., Elliott C.T., Stitt A.W. Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. J. Biol. Chem. 2010, 285:23137-23146.
89. Xie J., Burz D.S., He W., Bronstein I.B., Lednev I., Shekhtman A. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J. Biol. Chem. 2007, 282:4218-4231.
90. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002, 110:669-672.
91. Chinkers M., Wilson E.M. Ligand-independent oligomerization of natriuretic peptide receptors. Identification of heteromeric receptors and a dominant negative mutant. J. Biol. Chem. 1992, 267:18589-18597.
92. Horie R., Watanabe T., Morishita Y., Ito K., Ishida T., Kanagae Y., Saito I., Higashihara M., Mori S., Kadin M.E., Watanabe T. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 2002, 21:2493-2503.
93. Chan F.K., Chun H.J., Zheng L., Siegel R.M., Bui K.L., Lenardo M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000, 288:2351-2354.